A small biotech sponsor needed support for a Phase II study of an antipsychotic therapy in acute schizophrenia. With limited internal clinical operations experience and complex inpatient study design, the sponsor chose Worldwide Clinical Trials for our strong execution and guidance capabilities. This required operational flexibility and rapid scaling. Working as part of the sponsor’s team, Worldwide transformed a Phase II study into a broader neuroscience development partnership, supporting multiple indications and long-term growth.
Read the full case study to learn how Worldwide, by combining agile execution, engaging senior leadership, and providing strategic consultancy, supported the successful delivery of the initial study and the sponsor’s broader objectives.
